ENKAM Pharmaceuticals a step closer to testing promising drug  

2004.03.31
The Danish company has filed an application with the UK health authorities for permission to test its promising Alzheimer's drug

The Danish biotech company ENKAM Pharmaceuticals has filed an application with the UK health authorities for permission to test its promising drug for the treatment of Alzheimer's disease in the UK. Morten Albrechtsen, managing director of ENKAM Pharmaceuticals says the UK has been chosen because it has great experience with early clinical trials.

 

The clinical trial will include 48 patients with incipient Alzheimer's disease and mild cognitive impairment, the latter considered to be an early stage of Alzheimer's disease. The patients will receive a peptide FGLL which has been tested in animals with Alzheimer-like conditions. The animal experiments showed that FGLL prevented destruction of nerve cells and normalised memory.

 

ENKAM Pharmaceuticals was established in 2000 as a spin-off from Copenhagen University and develops treatments for CNS disorders. Investors in ENKAM Pharmaceuticals include Migrata UK and Vangelis which jointly have invested DKK 14 million (USD 2.2 million). The news is reported by BiotechDenmark online and on ENKAM Pharmaceuticals website.

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×